A Leishmaniose Tegumentar é uma doença infecciosa negligenciada, endêmica em 13 países da América, tendo o Brasil como responsável por 96% das notificações. O tratamento de primeira linha antimoniato N-metil-glucamina (Glucantime), droga parenteral e com várias contraindicações, que dificulta seu uso regiões isoladas do nosso país, justamente onde a maior incidência ocorre. Em 2020 Ministério S...

Background: The adverse effects and increased resistance of drugs necessities the discovery novel combination therapy. Objectives: This study aimed to examine Artemisinin plus glucantime or shark cartilage extract on Iranian strain Leishmania major (MRHO/IR/75/ER) in vitro vivo. Methods: In experiments, their different concentrations (3.12 - 400 µg/mL) promastigotes, amastigotes, un-infected ma...

In this study we examined enhancement effects of Artemisinin plus Glucantime and shark cartilage extract, on promastigotes and amastigotes of L.infantum in in vitro condition.The toxicity of artemisinin, glucantime and shark cartilage extract on the L. infantum promastigotes and amastigote-infected macrophages was evaluated using MTT assay. The role of these drugs in inducing apoptosis in proma...

The leishmanicidal activity of four batches of meglumine antimoniate, produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime-Aventis Pharma Ltda. Using the amastigote-like in vitro model, the active concentrations of Sb v varied from 10microg/ml to 300microg/ml for L. (L.) chagasi and from 50microg/ml to 300microg/ml for L. (L.) amazonensis, with no statistica...

OBJECTIVES Intralesional injection of pentavalent antimoniate is recommended by the World Health Organization for the treatment of cutaneous leishmaniasis (CL). This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®) ) and its influence on clinical laboratory parameters. METHODS A total of 105 patients with suspected lesions and ther...

BACKGROUND Recent circumstantial evidences are suggesting that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime®). Pistacia atlantica is native plant in Iran (central, western, and eastern regions). Gum obtained Pistacia atlantica has been reported to possess considerable in vitro antimicrobial activity. In this study, w...

Pentamidine was compared with meglumine antimoniate (Glucantime) for 80 patients with cutaneous leishmaniasis due to Leishmania braziliensis in Peru. Of the 40 patients administered Glucantime (20 mg of antimony [Sb]/kg/day intravenously for 20 days), 31 cured (78%), 6 failed (15%), of which 5 were due to relapse, and 3 were lost to follow-up (7%). Of the 40 patients administered pentamidine (2...

Toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (CVL). Twenty healthy mo...

BACKGROUND & OBJECTIVES Leishmaniasis is a parasitic disease transmitted by sand flies. Many investigations are performed to find an effective and safe treatment for leishmaniasis. In this study, we evaluated the efficacy of herbal extracts of Thymus vulgaris (Thyme) and Achillea millefolium (Yarrow), propolis hydroalcoholic extract and systemic glucantime against cutaneous leishmaniasis in Bal...